Qihan Biotech Receives FDA IND Clearance for QT-019C Universal CAR-T Therapy Targeting Autoimmune Diseases
核心洞察
Qihan Biotech (搜索) announced FDA IND clearance for QT-019C (搜索), a universal allogeneic CAR-T (搜索) cell therapy that potentially eliminates the need for lymphodepleting chemotherapy preconditioning.
QT-019C (搜索) represents one of the first CAR-T (搜索) products to advance into human clinical trials under FDA approval with minimal preconditioning requirements for autoimmune disease (搜索) treatment.
The therapy aims to expand CAR-T (搜索) treatment access to a broader range of autoimmune disease (搜索) patients by offering a safer and more convenient treatment option.
Qihan Biotech (搜索), a biotechnology company specializing in high-throughput, multiplexed gene editing technologies for cell therapy and organ transplantation, has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for QT-019C (搜索), a universal allogeneic CAR-T (搜索) cell therapy. The announcement, made on May 20, 2026, represents a significant milestone in the development of next-generation cell therapies for autoimmune diseases.
Revolutionary Approach to CAR-T Therapy
QT-019C (搜索) distinguishes itself through its potential to reduce or even eliminate the need for patients to receive preconditioning with lymphodepleting chemotherapy before receiving therapy. This innovation addresses a critical limitation in current CAR-T (搜索) applications, as the therapy is among the first such products to advance into human clinical trials under an FDA-approved IND with this capability.
The development represents a paradigm shift in autoimmune disease (搜索) treatment, where CAR-T (搜索) application has traditionally been limited to the most severely affected patients due to the requirement for lymphodepletion preconditioning. Qihan Biotech (搜索) has leveraged its multiplexed gene editing technological innovations to develop QT-019C (搜索) with the specific goal of offering a broader range of patients with autoimmune disease a safer and more convenient treatment option.
Addressing Universal Cell Therapy Challenges
QT-019C (搜索) has been developed with a strong focus on clinical needs and incorporates three major innovations aimed at delivering a next-generation therapy that requires minimal lymphodepletion while maintaining safety, efficacy, and affordability. The therapy represents Qihan Biotech (搜索)'s proprietary intellectual property and demonstrates the company's commitment to advancing off-the-shelf cell therapies.
Clinical Significance and Market Impact
This milestone marks a significant advancement in the field of next-generation off-the-shelf cell therapies, potentially transforming the treatment landscape for autoimmune diseases. By addressing the multiple challenges currently facing universal cell therapies, QT-019C (搜索) could expand access to CAR-T (搜索) treatment for patients who previously could not tolerate the intensive preconditioning requirements.
The FDA IND clearance enables Qihan Biotech (搜索) to proceed with human clinical trials, bringing this innovative therapy closer to patients who could benefit from a more accessible and safer CAR-T (搜索) treatment option. The development underscores the growing potential of multiplexed gene editing technologies in creating more practical and widely applicable cell therapies.